Clinical Trial Update: Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Brentuximab Vedotin + DHAP in relapsed or refractory classical Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• DHAP (dexamethasone, high-dose cytarabine, cisplatin)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Relapsed/Refractory Classical Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN